Allan Goldberg
Managing Partner, Aquarius Capital Corporation

Allan has been a biotechnology entrepreneur, CEO, Board member, and advisor for both private and public companies with marketed and R&D stage products. He has been involved primarily in therapeutics companies focused either on oncology or infectious disease. Currently, he is on the Board of Orbis Diagnostics, a company developing a rapid, quantitative, low-cost, portable point-of-care diagnostic platform technology that will be used initially to detect neutralizing antibodies after SARS-CoV-2 infection, but that also has broad applicability for detection of other infectious agents.

He is a Managing Partner of Aquarius Capital Corporation that seeks to help early to mid-stage companies having disruptive technologies. The group invests in and advises companies in digital health, medical devices, and diagnostics.

Allan has been on the boards of several non-profit organizations, including the Summit School and the Madden Open Hearts Camp. In addition, he has been active in Princeton alumni activities and was the President of the Association of Princeton Graduate Alumni.

Prior to entering the biotech industry, he was a professor of virology at The Rockefeller University, where his lab focused on viral oncology. Allan holds a B.A. from Cornell University and a Ph.D. in Biochemistry/Biology from Princeton University.